-
1.
公开(公告)号:WO2009149189A3
公开(公告)日:2010-03-04
申请号:PCT/US2009046137
申请日:2009-06-03
Applicant: ABBOTT LAB , GHAYUR TARIQ , ISAKSON PETER C , OLSON LISA M , WU CHENGBIN , HUGUNIN MARGARET , KAMATH RAJESH V , CUFF CAROLYN A , ALLEN HAMISH J
Inventor: GHAYUR TARIQ , ISAKSON PETER C , OLSON LISA M , WU CHENGBIN , HUGUNIN MARGARET , KAMATH RAJESH V , CUFF CAROLYN A , ALLEN HAMISH J
CPC classification number: C07K16/2887 , A61K39/3955 , A61K45/06 , A61K47/48546 , A61K47/6845 , A61K2039/505 , A61K2039/70 , C07K16/22 , C07K16/241 , C07K16/244 , C07K16/245 , C07K16/247 , C07K16/248 , C07K16/2866 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/64 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , G01N33/6869 , G01N2333/545
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白,制备方法,具体涉及用于预防,诊断和/或治疗疾病的用途。
-
公开(公告)号:WO2008127271A3
公开(公告)日:2009-04-09
申请号:PCT/US2007019660
申请日:2007-09-07
Applicant: ABBOTT LAB , WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Inventor: WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
Abstract translation: 本发明包括IL-13结合蛋白。 具体地,本发明涉及作为嵌合,CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力,并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性,例如在患有hTL-13活性有害的病症的人类受试者中。
-
3.
公开(公告)号:EP2297209A4
公开(公告)日:2012-08-01
申请号:EP09759348
申请日:2009-06-03
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , ISAKSON PETER C , OLSON LISA M , WU CHENGBIN , HUGUNIN MARGARET , KAMATH RAJESH V , CUFF CAROLYN A , ALLEN HAMISH J
CPC classification number: C07K16/2887 , A61K39/3955 , A61K45/06 , A61K47/48546 , A61K47/6845 , A61K2039/505 , A61K2039/70 , C07K16/22 , C07K16/241 , C07K16/244 , C07K16/245 , C07K16/247 , C07K16/248 , C07K16/2866 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/64 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , G01N33/6869 , G01N2333/545
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
-
公开(公告)号:EP2064336A4
公开(公告)日:2010-03-17
申请号:EP07873427
申请日:2007-09-07
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号:ECSP10010644A
公开(公告)日:2011-02-28
申请号:ECSP10010644
申请日:2010-11-29
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , WU CHENGBIN , CUFF CAROLYN A , OLSON LISA , ISAKSON PETER C , HUGUNIN MARGARET , KAMATH RAJESH V , ALLEN HAMISH J
IPC: A61K39/395 , C07H21/04 , C12N1/10
Abstract: La presente invención se refiere a la ingeniería de proteínas de unión multivalentes y multiespecíficas, métodos de fabricación, y específicamente para su uso en la prevención, el diagnóstico y/o tratamiento de la enfermedad.
-
公开(公告)号:DOP2010000368A
公开(公告)日:2011-02-15
申请号:DO2010000368
申请日:2010-11-30
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , GHAYUR TARIQ , ISAKSON PETER C , OLSON LISA M , HUGUNIN MARGARET , KAMATH RAJESH V , CUFF CAROLYN A , ALLEN HAMISH J
Abstract: Proteínas de unión multivalentes y multiespecíflcas producidas por ingeniería genética, métodos para elaborarlas y, específicamente, sus usos en la prevención, el diagnôstico ylo el tratamiento de enfermedades.
-
公开(公告)号:AR072001A1
公开(公告)日:2010-07-28
申请号:ARP090101994
申请日:2009-06-03
Applicant: ABBOTT LAB
Inventor: KAMATH RAJESH V , CUFF CAROLYN A , ALLEN HAMISH J , GHAYUR TARIQ , ISAKSON PETER C , OLSON LISA M , WU CHENGBIN , HUGUNIN MARGARET
Abstract: Prote¡nas de union multivalentes y multiespec¡ficas producidas por ingenier¡a genetica, metodos para elaborarlas y, espec¡ficamente, sus usos en la prevencion, el diagnostico y/o el tratamiento de enfermedades. Conjugado de inmunoglobulina, cido nucleico, vector, celula huesped, metodo para producir la prote¡na de union, composicion farmaceutica. Reivindicacion 1: Una prote¡na de union que comprende una cadena polipept¡dica, caracterizada porque dicha cadena polipept¡dica comprende VD1-(X1)n-VD2-C-(X2)n, en donde; VD1 es un primer dominio variable de la cadena pesada; VD2 es un segundo dominio variable de la cadena pesada; C es un dominio constante de la cadena pesada; X1 es un conector, con la condicion de que no sea CH1; X2 es una region Fc; y n es 0 o 1; en donde la prote¡na de union es capaz de unir un par de ant¡genos seleccionados del grupo formado por TNF y lL-17A; TNF y RANKL; TNF y VEGF; TNF y SOST; TNF y DKK; TNF y alfaVbeta3; TNF y NGF; TNF y IL-23p19; TNF y IL-6; TNF y IL-6R; TNF y CD-20; IgE y lL-13; lL-13 y IL-23p19; IgE y lL-4; IgE y IL-9; lL-13 y IL-9; IL-l3 y IL-4; IL-6R y VEGF; IL-6R y lL-17A; IL-6R y RANKL; IL-17A y IL-1beta; IL-1beta y RANKL; IL-1beta y VEGF; RANKL y CD-20; y IL-1alfa y IL-1beta.
-
公开(公告)号:ZA200901526B
公开(公告)日:2018-11-28
申请号:ZA200901526
申请日:2009-03-03
Applicant: ABBOTT LAB
Inventor: MELIM TERRY L , CUFF CAROLYN A , ARGIRIADI MARIA A , WU CHENGBIN , HINTON PAUL R , DIXON RICHARD W , KUMAR SHANKAR , BELK JONATHAN P , CHEN YAN , YING HUANG
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号:CA2662701C
公开(公告)日:2015-12-08
申请号:CA2662701
申请日:2007-09-07
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
IPC: C07K16/24 , A61K39/395 , A61K47/48 , A61K49/00 , A61K51/10 , C07K16/46 , C12N15/13 , C12N15/63 , C12P21/08
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
-
公开(公告)号:PE20100092A1
公开(公告)日:2010-03-12
申请号:PE2009000768
申请日:2009-06-03
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , ISAKSON PETER C , OLSON LISA M , WU CHENGBIN , HUGUNIN MARGARET , KAMATH RAJESH V , CUFF CAROLYN A , ALLEN HAMISH
Abstract: SE REFIERE A UNA INMUNOGLOBULINA CON DOMINIO VARIABLE DUAL QUE CONTIENE UNA PROTEINA DE UNION QUE COMPRENDE CADENAS POLIPEPTIDICAS TALES COMO: I) VD1-(X1)n-VD2-C-(X2)n DONDE VD1 Y VD2 SON EL PRIMER Y SEGUNDO DOMINIO VARIABLE DE LA CADENA PESADA RESPECTIVAMENTE Y COMPRENDEN UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LA SEQ ID Nº 28, 30, 32, 34, 36, 38, 40, 42, ENTRE OTROS; C ES UN DOMINIO CONSTANTE DE LA CADENA PESADA; X1 ES UN CONECTOR DIFERENTE DE CH1; X2 ES LA REGION Fc SELECCIONADA DE IgG1, IgG2, IgG3, ENTRE OTROS, Y DONDE X1 O X2 ES UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LA SEQ ID Nº 1-26; n ES 0 O 1; II) VD1-(X1)n-VD2-C-(X2)n DONDE VD1 Y VD2 SON EL PRIMER Y SEGUNDO DOMINIO VARIABLE DE LA CADENA LIVIANA RESPECTIVAMENTE Y COMPRENDEN UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LA SEQ ID Nº 29, 31, 33, 35, 37, 39, 41, 43, ENTRE OTROS; C ES UN DOMINIO CONSTANTE DE LA CADENA LIVIANA; X1 ES UN CONECTOR DIFERENTE DE CH1; X2 NO COMPRENDE UNA REGION Fc; n ES 0 O 1. DICHA PROTEINA DE UNION ES CAPAZ DE UNIR UN PAR DE ANTIGENOS TALES COMO TNF Y IL-17A, TNF Y RANKL, TNF Y VEGF, TNF Y IL-6, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE DICHA INMUNOGLOBULINA Y A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE ARTRITIS, LUPUS ERITEMATOSO SISTEMICO, ASMA, PSORIASIS, SINDROME NEFROTICO
-
-
-
-
-
-
-
-
-